Form 4: Catalyst Pharma CCO Del Carmen Reports Stock Transactions

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the vesting of restricted stock units and subsequent sale of shares for tax withholding purposes.

Summary

• Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on December 29, 2025.
• Acquired 8,667 shares of common stock upon the vesting of restricted stock units.
• Disposed of 3,839 shares of common stock to cover applicable withholding taxes related to the vesting.
• Following these transactions, Del Carmen beneficially owns 14,337 shares of common stock directly.
• Del Carmen also beneficially owns 1,036,846 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a routine vesting of restricted stock units and subsequent tax-related sale, which is a neutral event. The net increase in direct share ownership for the insider is a slight positive, indicating continued alignment with shareholder interests.

Positives

• Vesting of 8,667 restricted stock units indicates a successful milestone for the Chief Commercial Officer, converting contingent rights into actual equity.
• The retention of 4,828 net shares (8,667 acquired 3,839 disposed) demonstrates continued alignment of management's interests with shareholders.

Negatives

• The disposition of 3,839 shares, while for tax purposes, reduces the direct common stock holdings of the Chief Commercial Officer.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction disclosure and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard equity compensation practices within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The vesting and net retention of shares by a key executive aligns management's interests with shareholders, potentially signaling confidence.
• Employees: Reflects standard equity compensation practices, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of restricted stock units and a subsequent sale of shares to cover tax obligations by a Chief Commercial Officer. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or the executive's confidence. The net increase in the executive's direct share ownership, even after tax withholding, suggests continued alignment with shareholder interests. Therefore, the filing itself does not provide new information warranting a change in investment recommendation; a 'hold' stance is appropriate based solely on this disclosure.

Keywords

Catalyst Pharmaceuticals, CPRX, Jeffrey Del Carmen, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transaction, Chief Commercial Officer, Equity Compensation